218 related articles for article (PubMed ID: 33689138)
1.
Ma G; Liu C; Lian W; Zhang Y; Yuan H; Zhang Y; Song S; Yang Z
Ann Nucl Med; 2021 May; 35(5):600-607. PubMed ID: 33689138
[TBL] [Abstract][Full Text] [Related]
2. Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [
Elmi A; Makvandi M; Weng CC; Hou C; Clark AS; Mach RH; Mankoff DA
Clin Cancer Res; 2019 May; 25(10):3063-3073. PubMed ID: 30692100
[TBL] [Abstract][Full Text] [Related]
3.
Liu H; Sun H; Zhang B; Liu S; Deng S; Weng Z; Zuo B; Yang J; He Y
Breast Cancer; 2020 May; 27(3):372-380. PubMed ID: 31781983
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive
Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [
Zhao H; Meng H; Wen J; Wang C; Liu J; Huang G
Mol Imaging Biol; 2020 Jun; 22(3):772-779. PubMed ID: 31452065
[TBL] [Abstract][Full Text] [Related]
7. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
[TBL] [Abstract][Full Text] [Related]
8. 3'-[
Tatum JL; Kalen JD; Jacobs PM; Riffle LA; James A; Thang L; Sanders C; Hollingshead MG; Basuli F; Shi J; Doroshow JH
J Transl Med; 2022 Aug; 20(1):375. PubMed ID: 35982453
[TBL] [Abstract][Full Text] [Related]
9. Panitumumab-DOTA-
Facca VJ; Cai Z; Gopal NEK; Reilly RM
Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
[TBL] [Abstract][Full Text] [Related]
10. ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer.
Li Z; Belitzky E; Blaha O; Cavaliere A; Katz SR; Aboian M; Melegari L; Rajabimoghadam K; Kurpiewski S; Zhu X; Marquez-Nostra B
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900378
[TBL] [Abstract][Full Text] [Related]
11. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
12. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer.
Huang Y; Wu H; Li X
Cancer Cell Int; 2020; 20():501. PubMed ID: 33061853
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
McKnight BN; Kim S; Boerner JL; Viola NT
Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
[TBL] [Abstract][Full Text] [Related]
14. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
Liu CY; Lau KY; Hsu CC; Chen JL; Lee CH; Huang TT; Chen YT; Huang CT; Lin PH; Tseng LM
PLoS One; 2017; 12(12):e0189007. PubMed ID: 29261702
[TBL] [Abstract][Full Text] [Related]
15. PET imaging of early response to the tyrosine kinase inhibitor ZD4190.
Yang M; Gao H; Yan Y; Sun X; Chen K; Quan Q; Lang L; Kiesewetter D; Niu G; Chen X
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1237-47. PubMed ID: 21360246
[TBL] [Abstract][Full Text] [Related]
16. [18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors.
Seifert R; Küper A; Tewes M; Heuschmid M; Welt A; Fendler WP; Herrmann K; Decker T
Oncol Res Treat; 2021; 44(7-8):400-407. PubMed ID: 34102639
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway.
Li T; Zhang Q; Zhang J; Yang G; Shao Z; Luo J; Fan M; Ni C; Wu Z; Hu X
BMC Cancer; 2014 Feb; 14():96. PubMed ID: 24529079
[TBL] [Abstract][Full Text] [Related]
18. A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6.
Ji J; Zhang Z; He X; Pan G; Li G; Lv J; Xu Y; Xie M; Feng J; Wang W; Liu B; Ma J; Wang X
Anticancer Drugs; 2023 Aug; 34(7):803-815. PubMed ID: 36729405
[TBL] [Abstract][Full Text] [Related]
19. Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.
Fricke IB; De Souza R; Costa Ayub L; Francia G; Kerbel R; Jaffray DA; Zheng J
PLoS One; 2018; 13(5):e0196892. PubMed ID: 29723251
[TBL] [Abstract][Full Text] [Related]
20. Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in Vivo.
Li HC; Xia ZH; Chen YF; Yang F; Feng W; Cai H; Mei Y; Jiang YM; Xu K; Feng DX
Cell Physiol Biochem; 2017; 43(5):1829-1840. PubMed ID: 29050003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
